The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer

BACKGROUND: Lung cancer ranks as the most prevalent solid cancer in the world. The non-small-cell lung cancer (NSCLC) histological subtype accounts for the largest proportion of lung cancers. Even though neoadjuvant therapy has shown encouraging efficacy for resectable NSCLC, there is a lack of clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiangfeng, Li, Jianqiang, Cai, Lei, Chen, Sheng, Jiang, Youhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039669/
https://www.ncbi.nlm.nih.gov/pubmed/33850883
http://dx.doi.org/10.21037/atm-21-670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039669/
https://www.ncbi.nlm.nih.gov/pubmed/33850883
http://dx.doi.org/10.21037/atm-21-670

Ejemplares similares